10.1038/onc.2017.38 Summary Keywords alcohol-associated liver disease (ALD), glucagon-like peptide 1 receptor agonists (GLP-1 RAs), metabolic dysfunction and alcohol-associated liver disease (MetALD), metabolic dysfunction-associated steatotic liver disease (MASLD), steatotic liver disease (SLD) Citation Mahalingam S, Kharbanda KK, Casey CA and Rasineni K (2026) Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum
The figures above come from clinical trials, where people are usually monitored closely and given structured lifestyle support alongside medication
The first true oral GLP-1 competitor, orforglipron (Eli Lilly, brand name Foundayo), is a non-peptide agonist expected to launch at a significantly lower price point
Combined with guarana extract, which naturally contains caffeine, this formula is designed for individuals who want to complement their nutrition in a targeted way
This compound is not for human consumption
It is a combination stack of two tissue-repair peptides: BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4)